Impact of rheumatoid arthritis in Turkey: a questionnaire study

dc.authorid0000-0003-3800-7868
dc.authorid0000-0002-3718-171X
dc.authorid0000-0001-6625-1652
dc.authorid0000-0002-4860-9072
dc.authorid0000-0001-6214-1974
dc.authorid0000-0001-8219-3720
dc.contributor.authorDireskeneli, H.
dc.contributor.authorAkkoc, N.
dc.contributor.authorBes, C.
dc.contributor.authorCakir, N.
dc.contributor.authorCefle, A.
dc.contributor.authorCobankara, V.
dc.contributor.authorDalkilic, E.
dc.date.accessioned2025-05-10T19:28:35Z
dc.date.issued2014
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjective Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study.
dc.description.sponsorshipMerck Sharpe-Dohme Turkey, Merck & Co., Inc., Whitehouse Station, NJ, USA
dc.description.sponsorshipThe survey and manuscript was sponsored by Merck Sharpe-Dohme Turkey, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. The Investigators of the survey have received honoraria from MSD Turkey. No payments were made to authors for the writing of this manuscript.
dc.identifier.endpage483
dc.identifier.issn0392-856X
dc.identifier.issue4
dc.identifier.pmid24960289
dc.identifier.scopusqualityQ2
dc.identifier.startpage477
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7376
dc.identifier.volume32
dc.identifier.wosWOS:000341171000006
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherClinical & Exper Rheumatology
dc.relation.ispartofClinical and Experimental Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectrheumatoid arthritis
dc.subjectquality of life
dc.subjectpatient survey
dc.titleImpact of rheumatoid arthritis in Turkey: a questionnaire study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
7376
Boyut:
354.73 KB
Biçim:
Adobe Portable Document Format